Tenofovir Alafenamide

證據等級: L5

預測適應症: 3 個

Tenofovir Alafenamide: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Tenofovir alafenamide (TAF) is a nucleotide reverse transcriptase inhibitor prodrug whose established antiviral activity underlies its known use against HIV-1 (and, per its drug class, hepatitis B). The TxGNN model’s top-ranked prediction for this candidate is Feline Acquired Immunodeficiency Syndrome (FIV) — a lentiviral infection in cats — with 0 clinical trials and 0 publications currently supporting this specific link. This is a pure mechanism-based extrapolation with no empirical (animal or human) data behind it.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (inferred from mechanistic rationale; structured original-indication data not available)
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome (FIV)
TxGNN Prediction Score	99.89%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for tenofovir alafenamide is not available in this evidence pack (flagged as a data gap). Based on known pharmacology, TAF is a prodrug of tenofovir, a nucleotide analogue that inhibits reverse transcriptase — the enzyme lentiviruses (including HIV-1) require to replicate.

FIV, the feline analogue of HIV, is also a lentivirus. The TxGNN model appears to have drawn an analogy between TAF’s proven reverse-transcriptase-inhibiting activity against HIV-1/HBV and FIV’s shared lentiviral replication machinery. This is a biologically plausible mechanistic link, but it is purely a mechanism-level extrapolation: there is no clinical trial, no published in vitro/in vivo study, and no veterinary pharmacology data in this evidence pack that tests TAF against FIV specifically.

It is also important to note that FIV is a veterinary (feline) disease entity, not a human clinical indication. Even if the mechanistic rationale holds, this prediction as stated has no direct pathway to human therapeutic use and would need reframing (e.g., as a veterinary research signal) before it has any relevance to a South African human-health formulary decision.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Tenofovir alafenamide is currently not marketed in South Africa under this evidence pack, with 0 SAHPRA registrations on record. No product/registration-level detail is available to tabulate.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate rests entirely on a mechanistic analogy (shared lentiviral reverse transcriptase target) with zero supporting clinical trials, zero publications, and no confirmed original indication or MOA data on file. The predicted disease (FIV) is also a veterinary condition, not a human indication, further limiting immediate relevance.

To proceed, the following is needed:

TFDA/SAHPRA-approved Professional Information (label warnings and contraindications) — currently a blocking data gap preventing any safety pre-screening
Confirmed mechanism-of-action data via DrugBank query
Confirmed original approved indication(s) and licensing status
If pursuing a human-relevant repurposing signal from this drug, note that a related model output — simian immunodeficiency virus (SIV) infection — is backed by 1 clinical trial and 9 publications (all animal/preclinical, Tier 3), reflecting TAF’s established role as an HIV pre-exposure prophylaxis (PrEP) research tool; this may be a more productive avenue than the FIV signal evaluated here
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.